A planned 84-share sale leaves Revvity (RVTY) officer holding 7,117 shares directly.
Revvity's VP and CAO, Anita Gonzales, sold 84 shares of common stock on October 1, 2026, for $155.48 per share, as part of a pre-arranged Rule 10b5-1 trading plan established on November 7, 2025. Following this transaction, Gonzales directly holds 7,117 shares of Revvity stock. The sale was reported in a Form 4 filing with the SEC.
Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock?
Revvity (RVTY) has been upgraded to a Zacks Rank #2 (Buy), reflecting a positive shift in its earnings outlook. This upgrade is based on upward revisions in earnings estimates, which Zacks' research indicates is a powerful indicator of future stock price movements. Investors are encouraged to consider this upgrade as a sign of improving underlying business for Revvity.
Revvity (RVTY) Upgraded to Buy: What Does It Mean for the Stock?
Revvity (RVTY) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates, indicating a positive outlook for the company's financial performance. This upgrade suggests potential buying pressure and an increase in the stock price, as changes in earnings estimates are a strong indicator of near-term stock movements. The company is expected to earn $5.36 per share for the fiscal year ending December 2026, with estimates having risen by 2.2% over the past three months.
Revvity Goes Higher on Q3 Figures
Revvity, Inc. (NYSE: RVTY) announced it would release its Q3 2026 financial results before market open on Tuesday, November 3, 2026, followed by a conference call. The company, a health science solutions provider with 2025 revenue of $2.9 billion, saw its shares jump by $2.26, or 1.5%, to $151.45 following the news.
Form 144 REVVITY For: 1 October By Investing.com
This article from Investing.com reports the filing of Form 144 for REVVITY on October 1st. It's a very brief news item, noting the stock symbol RVTY and its minor price change. The content primarily highlights the publication of this regulatory form.
An officer proposes selling 84 Revvity (NYSE: RVTY) shares valued at $13.1K.
Revvity officer Anita Gonzales has proposed selling 84 shares of common stock, valued at $13,060.32, with Fidelity Brokerage Services LLC as the broker and an approximate sale date of October 1, 2026. This notice also reports a previous sale of 85 shares by Gonzales on July 20, 2026, totaling $9,305.80. The filing, categorized as Form 144, details the terms of restricted stock vesting and the role of an attorney-in-fact in the transaction.
Revvity (RVTY): Buy, Sell, or Hold Post Q2 Earnings?
This article analyzes Revvity (RVTY) after a significant stock price increase, questioning whether it's a buying opportunity or a risk. The analysis highlights concerns such as declining revenue, slow organic growth, and decreasing EPS, suggesting the company may underperform despite its recent rally. The report concludes that Revvity is currently overvalued at 26.7x forward P/E and advises investors to look elsewhere.
Revvity (RVTY): Buy, Sell, or Hold Post Q2 Earnings?
This article analyzes Revvity (RVTY) after a significant stock price surge, questioning its long-term viability despite recent gains. The analysis highlights concerns over declining revenue, slow organic growth, and decreasing earnings per share, concluding that the stock is overvalued at its current forward P/E. The authors advise against investing in Revvity and suggest alternative high-quality stocks.
Revvity (RVTY) Launches T1D Screening Kit, Is The Upside Already Priced In?
Revvity (RVTY) has launched a new CE-IVDR-certified GSP T1D 3plex kit for population-wide screening of type 1 diabetes in children. Despite recent stock performance showing significant gains over the last year, the company's valuation currently indicates it is about 20% overvalued compared to the most followed fair value estimate. The article discusses this launch in the context of Revvity's stock momentum and valuation concerns, noting potential risks from reimbursement changes or funding weaknesses.
Revvity stock last trades at USD 150.00 on September 28, 2026
Revvity (RVTY) shares closed at USD 150.00 on September 28, 2026, marking a 0.73 percent decrease. This comes after the company recently launched a new diabetes screening kit and announced its intention to acquire Human Cell Design, a company specializing in human cell models for metabolic diseases. The acquisition is expected to finalize in Q4 2026, pending regulatory approvals.
Revvity Launches IVDR-Certified Triplex Autoantibody Assay for Early Type 1 Diabetes Screening
Revvity has launched the GSP T1D 3plex kit, an IVDR-certified, multiplex autoantibody detection solution for early Type 1 Diabetes screening in children. This fully automated assay uses dried blood spots and Revvity’s high-throughput GSP instrument to identify at-risk individuals before symptom onset, facilitating early intervention. The kit will be rolled out initially in Europe and other markets accepting CE-IVD-marked products, supporting population-level screening programs.
PKI4882935 Bond Profile: Coupon and Redemption
This article provides a detailed bond profile for Revvity, Inc.'s PKI4882935 bond, highlighting key facts such as issuer information, issue and maturity dates, and face value. It outlines the company's segments (Life Sciences and Diagnostics) and offers insights into the bond's classification, credit risk assessment, and detailed interest payment schedule. The bond has a 3.3% semi-annual fixed coupon rate and an outstanding amount of $850.00 million USD.
Did Diabetes Screening Kit Launch Just Shift Revvity (RVTY) Stock Investment Narrative?
Revvity recently launched a CE IVDR certified GSP T1D 3plex kit for early type 1 diabetes screening, aligning with its strategy for higher-margin diagnostics. While this launch supports the long-term investment narrative by expanding recurring consumables demand, it doesn't immediately change the near-term picture, which remains focused on margin improvement amidst regulatory and reimbursement pressures. Analysts' opinions on Revvity's future diverge, with some optimistic about software and genomics automation, but the company faces risks including pricing pressure and a projected 17% potential downside to its current price based on fair value estimates.
New Products: Qiagen, Helix, Countable Labs, AtlasBio, Revvity, Agilent
This article lists new product releases from several companies in the biotechnology and life sciences sectors. The companies mentioned include Qiagen, Helix, Countable Labs, AtlasBio, Revvity, and Agilent. The brief entry indicates a focus on new technologies and offerings in the market.
RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection
Revvity, Inc. (RVTY) has launched the GSP T1D 3plex kit in Europe, an automated solution for population-wide screening of newborns at risk for type 1 diabetes using dried blood spot samples. This kit is CE-IVDR-certified and aims to support early detection before symptoms appear, strengthening Revvity's diabetes portfolio. The company's stock saw a 6% gain following the announcement, reflecting positive investor response to this expansion into early T1D screening.
Revvity introduces GSP T1D 3plex kit for type 1 diabetes detection
Revvity has launched the GSP T1D 3plex kit, a CE-IVDR-certified, fully automated test designed for population screening of children at risk of type 1 diabetes (T1D). The kit uses capillary dried blood spot samples processed on Revvity’s GSP instrument, aiming for earlier detection to support early intervention. Initially available in Europe and markets accepting CE IVD-marked products, this launch expands Revvity's child health screening offerings.
Full Transcript: Revvity Q2 2026 Earnings Call
Revvity reported strong Q2 2026 results with 3% pro forma organic growth, exceeding revenue and EPS guidance due to robust diagnostics performance and unexpected tariff refunds. The company is divesting its China immunodiagnostics business by late 2027 to focus on higher-return markets and sees increased demand for AI-driven science tools, leading to a significant instrument backlog. Revvity raised its full-year guidance for organic growth to 4-5% and adjusted EPS to $5.30-$5.40, reflecting improved market conditions and strategic reinvestments.
Revvity stock gains 5.2 percent ahead of the open
Revvity stock gained 5.2 percent on September 24, 2026, closing at USD 149.49 on the NYSE, outperforming the Nasdaq Composite. A brokerage raised its price target for Revvity to USD 160 from USD 145 while maintaining a positive rating. The company also announced a quarterly dividend of USD 0.07 per share, with an ex-dividend date of October 23, 2026.
HCA Healthcare faces securities fraud investiga...
HCA Healthcare is under investigation for securities fraud after significantly cutting its full-year 2026 profit guidance, which led to a nearly 7% stock drop. The cut was attributed to an unfavorable shift in its payer mix, resulting in a $400 million revenue reduction in Q2. Pomerantz LLP is investigating potential unlawful practices, and affected investors are encouraged to contact the law firm for class action participation.
Revvity Inc stock hits 52-week high at 149.72 USD
Revvity Inc. (RVTY) stock has reached a new 52-week high of $149.72, representing a 62% surge in the last six months and an impressive 79.46% increase over the past year. Despite its strong performance, InvestingPro data suggests the stock might be overvalued. The company recently reported Q2 earnings exceeding expectations, driven by strong organic growth, improved margins, and increased demand related to artificial intelligence, leading to raised price targets from analysts like Stifel.
Charles River Laboratories International Jumps 5.1% in Broad Rally
Charles River Laboratories International (CRL) saw its stock surge 5.1% to $291.40, part of a broad rally across the diagnostics and research sector. This movement, echoed by peers like Revvity and Thermo Fisher, suggests investor optimism for the broader healthcare and research space rather than company-specific news. Investors are advised to monitor sector trends and potential catalysts for sustained momentum.
Is Revvity Stock Outperforming the Dow?
Revvity, Inc. (RVTY) is a large-cap health sciences company that has significantly outperformed the Dow Jones Industrial Average (DOWI) year-to-date and over the past year. The company's strong performance is attributed to its diagnostics segment and increasing demand from AI-driven life sciences, despite a recent slip from its 52-week high. Wall Street analysts maintain a "Moderate Buy" rating for RVTY.
Agilent Technologies stock hits 52-week high at 169.07 USD
Agilent Technologies (NYSE: A) stock recently hit a 52-week high of $169.07, demonstrating significant investor confidence and strong market performance with a 37.56% increase over the past year and a 45.37% return in six months. This surge is supported by 11 analysts revising earnings upwards and stronger-than-expected fiscal third-quarter results, prompting raised price targets from multiple firms. Despite these positive indicators, InvestingPro data suggests the stock might be overvalued relative to its Fair Value estimate.
Revvity launches type 1 diabetes screening kit in Europe
Revvity Inc. (NYSE:RVTY) has launched its GSP T1D 3plex kit in Europe, a CE-IVDR-certified screening solution designed to identify children at risk of developing type 1 diabetes before symptoms manifest. The kit utilizes dried blood spots and Revvity’s GSP instrument for early detection, aiming to improve outcomes by allowing intervention before significant beta-cell damage. This initiative expands Revvity's child health screening efforts and will be detailed at the European Association for the Study of Diabetes conference.
Top Midday Stories: Oracle's Data Center Delay; People Withdraws MGM Offer; Revvity's New Diabetes Test
This article covers the top midday financial stories, including Oracle's data center delays, People withdrawing its offer for MGM, and Revvity's development of a new diabetes test. All three major US stock indexes were down in late-morning trading due to market uncertainty. The full article content is behind a premium paywall.
Form 4 Revvity Inc For: 23 September
This article from Investing.com reports on a Form 4 filing for Revvity Inc. related to September 23. It's a very brief news item, primarily serving as an announcement of the filing without further details in the provided content. The article includes stock market data and other news headlines.
Revvity CFO Maxwell Krakowiak sells $235,728 in RVTY stock By Investing.com
Revvity CFO Maxwell Krakowiak sold 1,631 shares of RVTY stock for a total of $235,728 on September 21, 2026, pursuant to a pre-arranged 10b5-1 trading plan. The sale occurred while shares were near a 52-week high and InvestingPro analysis suggests the stock is currently overvalued. Krakowiak now directly holds 14,781 shares.
After selling 1,631 shares, Revvity (RVTY) CFO holds 14,781 shares
Revvity's CFO, Maxwell Krakowiak, sold 1,631 common shares on September 21, 2026, at a price of $144.53 per share. This transaction was conducted under a pre-arranged 10b5-1 trading plan. Following the sale, Krakowiak directly holds 14,781 shares of Revvity stock.
Is Revvity Stock Outperforming the Dow?
Revvity, Inc. (RVTY), a leading health sciences solutions provider, has shown strong stock performance, gaining 44.7% over the last three months and 48.1% year-to-date, significantly outperforming the Dow Jones Industrials Average. The company's success is attributed to its diagnostics strength, AI-driven demand in life sciences, and strategic reinvestments. Analysts are moderately bullish on RVTY, with a consensus "Moderate Buy" rating.
Is Revvity Stock Outperforming the Dow?
Revvity, Inc. (RVTY), a health sciences solutions provider, has shown strong stock performance, outperforming the Dow Jones Industrials Average ($DOWI) over the past three months, year-to-date, and the last 52 weeks. The company's growth is attributed to its comprehensive life sciences and diagnostics portfolio, accelerating AI-driven demand, and strong performance in reproductive health and immunodiagnostics. Analysts maintain a "Moderate Buy" rating, with potential for further upside.
Revvity, Inc. (RVTY) latest stock news and headlines – Yahoo Finance
This Yahoo Finance page provides the latest stock news and headlines for Revvity, Inc. (RVTY), including its current stock price, dividend announcements, and recent news articles from various financial sources. It covers topics such as market shifts, acquisitions, earnings reports, and analyst opinions on RVTY's performance and future outlook. The page also includes performance metrics, comparing RVTY's returns against the S&P 500.
Revvity stock holds near USD 143 after target hike
Revvity Inc. (RVTY) stock closed at $143.45 on September 21, 2026, after Goldman Sachs raised its target price from $100 to $140, maintaining a Neutral rating. The company's Q2 revenue increased by 4.5 percent year-over-year, exceeding analyst expectations. Despite the target hike, the stock remained below its 52-week high, with its market capitalization at approximately $16.023 billion.
Revvity (NYSE: RVTY) shareholder may sell stock under Rule 144
A Form 144 SEC filing indicates that Maxwell Krakowiak, a shareholder of Revvity (RVTY), intends to sell up to 1,631 shares of common stock with an aggregate market value of $235,728.43. These shares are restricted stock that vested on several dates between March 2023 and September 2025, issued as compensation. The sale is expected to occur on or about September 21, 2026, through Fidelity Brokerage Services LLC on the NYSE.
Senior Vice President of Global Operations Tajinder Vohra Sold A Bunch Of Shares In Revvity
Tajinder Vohra, Revvity's Senior Vice President of Global Operations, recently sold shares worth US$1.0 million at an average price of US$141, reducing their holding by 38%. This marks the largest insider sale at Revvity in the last year, suggesting insiders found a lower price acceptable. Despite the sale, insiders still own 0.4% of Revvity shares, valued at about US$67 million, indicating some alignment with shareholders.
Why AbCellera Biologics (ABCL) Is Back In The Spotlight
AbCellera Biologics (ABCL) is gaining attention due to an upcoming oral presentation of Phase 2 data for its menopause drug, ABCL635. The company has shown strong recent share price momentum with a 90-day return of 128.39% and a year-to-date return of 268.22%, despite reporting modest revenue and a sizeable loss. Analysts currently tag AbCellera Biologics as 13.6% undervalued, with a fair value of $14.63, suggesting potential for further upside.
Revvity Inc. stock slips after CFRA downgrade but stays near 52-week high
Revvity Inc. stock eased after CFRA cut its rating to Hold on September 18, 2026, though the price target was raised to USD 157. The shares closed at USD 143.60, just below a fresh 52-week high reached earlier in the week. This downgrade and recent insider sale followed a strong rally in the stock, which was boosted by deal activity including the acquisition of Human Cell Design.
ETFs Investing in Revvity, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Revvity, Inc. (RVTY), a health technology company. It provides detailed financial information for each ETF, including market value, weight of RVTY stock, issuer, management style, expense ratio, and performance metrics. The aim is to help investors find accessible and lower-risk opportunities to invest in Revvity, Inc. through diversified funds.
Insider Tajinder Vohra Sells 7,330 Shares of Revvity Inc (RVTY)
Insider Tajinder Vohra sold 7,330 shares of Revvity Inc (RVTY) on September 16, 2026, reducing their total holdings to 6,635 shares. This sale is part of a broader pattern of insider selling at Revvity, with 8 insider sells and no buys over the past year, and the stock is considered "Modestly Overvalued" by GuruFocus.
Insider at Revvity (RVTY) sells stock under preset plan
Tajinder S. Vohra, Senior Vice President of Global Operations at Revvity (RVTY), sold 7,330 shares of common stock on September 16, 2026, for $140.88 per share, totaling approximately $1.03 million. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 15, 2026. Following the sale, Vohra directly holds 6,635 shares of Revvity common stock.
Revvity Stock Climbs 21% On A 5-Day Winning Streak
Revvity (RVTY) stock has seen a significant surge, gaining 21% over five consecutive trading days, adding approximately $2.9 billion to its market value. Despite this strong performance, the article highlights that the stock's valuation, at a 68.9 price-to-earnings multiple, is well above its Health Care sector peers, and its revenue growth and operating margin are below sector medians. The rally followed recent presentations at healthcare conferences, where management discussed margin targets and cash-flow expectations.
Revvity SVP Tajinder Vohra Sells 7,330 Shares Under 10b5-1 Trading Plan
Tajinder S. Vohra, Senior Vice President of Global Operations at Revvity, Inc. (NYSE:RVTY), reported the sale of 7,330 shares of common stock on September 16, 2026, under a Rule 10b5-1 trading plan. The shares were sold at $140.88 each, leaving Vohra with 6,635 shares directly owned after the transaction. The 10b5-1 plan was adopted on May 15, 2026.
A €6.3 million French program will test one blood marker to spot sepsis early
VolitionRx's Nu.Q NETs H3.1 assay has been chosen as the sole biomarker for a €6.3 million French government-funded program, DETECSEPS, aimed at the real-world early detection of sepsis. This initiative combines a clinical score with Volition's biomarker to assess sepsis risk in emergency departments, with results available within an hour. The program seeks to improve patient outcomes, reduce healthcare burden, and address the significant global and national mortality rates associated with sepsis.
The largest med-device firms in Mass. collectively increased revenue in 2025
The 20 largest medical device firms in Massachusetts experienced a collective revenue increase from 2024 to 2025. This article lists the top four firms based on their total 2025 revenue, including Thermo Fisher Scientific Inc., Boston Scientific Corp., Fresenius Medical Care, and Revvity Inc., detailing their revenues, employee numbers, and addresses.
Here’s How Much You Would Have Made Owning Revvity Stock In The Last 15 Years
Revvity (NYSE: RVTY) has shown strong performance over the past 15 years, outperforming the market with an average annual return of 14.61%. An investment of $1000 in RVTY 15 years ago would now be worth $7,469.50. This demonstrates the significant impact of compounded returns on investment growth.
Viatris Inc. (VTRS) latest stock news and headlines
This article provides a compilation of recent news and headlines concerning Viatris Inc. (VTRS), a pharmaceutical company. It highlights recent drug approvals, financial performance, analyst ratings, and various market insights related to the company's stock. The collection of articles offers a comprehensive overview of Viatris's current standing and market perception.
Revvity Jumps 6.1% Amid Sector-Wide Rally
Revvity, Inc. saw a significant 6.1% increase in its stock price on Tuesday, closing at $136.29, as part of a broad sector-wide rally benefiting diagnostics and research companies. The surge, which included a trading volume of 360,136 shares, suggests a positive shift in investor sentiment towards healthcare equipment and research, potentially driven by anticipated industry catalysts. Investors are advised to monitor the continuation of this sector momentum and Revvity's sustained outperformance.
RVTY Stock Rallies As Analysts Hike Targets And Deal Flow Builds
Revvity Inc. (RVTY) stock rallied by 8.96% following upbeat earnings and guidance, driven by strong investor optimism. KeyBanc, Baird, and UBS raised their price targets, citing improved Q2 trends, AI-driven screening demand, and the strategic acquisition of Human Cell Design to bolster diabetes and obesity research. While analysts are mostly positive, some caution against long-term growth durability and highlight the stock's premium valuation.
Revvity extends gains with another 9% advance, sets new high (RVTY:NYSE)
Revvity (RVTY), a health science technology company, saw its stock climb almost 9% to a new 52-week high, extending a recent strong advance for its third consecutive day of gains. The rally is attributed to broader sector strength, positive pipeline developments, and strategic acquisitions like Human Cell Design.
Revvity Inc stock hits 52-week high at 133.14 USD
Revvity Inc. stock reached a new 52-week high of $133.14, currently trading at $133.58, reflecting a strong performance with over 50% growth in the last six months. This surge follows the company's strong second-quarter earnings, which surpassed analyst expectations due to robust organic growth and AI-linked demand. Despite a warning from InvestingPro about potential overvaluation, analysts like Stifel and RBC Capital have acknowledged the positive developments, though noting some long-term growth challenges.
Q2 Rundown: Revvity (NYSE:RVTY) Vs Other Research Tools & Consumables Stocks
The article reviews the Q2 performance of Revvity (NYSE:RVTY) and other companies in the research tools & consumables industry. It highlights Revvity's strong quarter with revenues of $711.1 million, while also detailing the best performer, Avantor (NYSE:AVTR), and the weakest, Bruker (NASDAQ:BRKR), among its peers. The sector as a whole reported strong Q2 results, with revenues beating consensus estimates by 1.7%.
